ACE-Inhibitors in High Vascular Risk: From Experimental Medicine toClinical Trials

Copyright: © 2013 Angeli F. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The Renin-Angiotensin System (RAS) is a complex regulatory system with many identifiable actions. It may primarily be viewed as a powerful regulatory system for the conservation of salt, blood volume and Blood Pressure (BP) [1]. However, an increased activity of the RAS, especially in combination with other cardiovascular (CV) risk factors, may lead to a cascade of deleterious effects.